Objectives The factors associated with hepatitis C virus (HCV) treatment uptake and responses were assessed among HCV/HIV co-infected individuals referred for HCV therapy at an urban HIV clinic.
Introduction
Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in HIV co-infected patients [1] [2] [3] . It is estimated that 74-86% of individuals infected with HCV will progress to chronic disease [4, 5] . Further, evidence indicates that approximately one-third of individuals infected with HCV will progress to cirrhosis and end-stage liver disease within 20-30 years [6, 7] , and that those with HIV/HCV co-infection, more frequently, have more severe and quicker progression of their HCV disease [8] [9] [10] . Unfortunately, few HIV/HCV co-infected patients ever receive HCV treatment [11, 12] . When providers are questioned, reasons for patients not receiving HCV therapy are varied, and include decompensated liver disease, comorbid illness, ongoing substance use issues, and psychiatric illness, and provider bias and patient choice [10, 13, 14] . Patient described factors that act as treatment barriers in HCV/HIV co-infected individuals include fear and vicarious experiences, whereas facilitating factors include patient-provider relationships, gaining sober time, and facing treatment head-on [15] .
Earlier studies have generally shown discouragingly low rates of HCV treatment uptake in HCV/HIV co-infected populations. HCV treatment uptake as low as 1.1 and 3.4% in all HCV infected and HCV/HIV co-infected patients, respectively, has been reported [12, 16] , whereas treatment uptake as high as 10 .4% has been shown in HCV/HIV coinfected patients screened and referred for therapy [12] .
Barriers to successful treatment of HCV do not end with treatment initiation. Patients who do start HCV therapy often experience side-effects resulting in diminished adherence to treatment regimens. It is estimated that 10-20% of patients being treated for HCV discontinue therapy secondary to side-effects, whereas a further 20-30% will require dose modification, with resultant decrease in sustained virological response (SVR) [17] .
The aim of this study was to examine the uptake and outcomes of HCV treatment between HCV/HIV coinfected individuals attending an urban multidisciplinary primary and specialty care clinic, located in Vancouver, British Columbia, Canada. Starting in 2002, we actively recalled HIV/HCV co-infected individuals registered in the clinic who had no known contraindications to HCV treatment. We assessed the factors associated with treatment uptake and response among returning patients who were deemed eligible for HCV therapy.
Materials and methods

Study setting
The John Ruedy Immunodeficiency clinic, at St Paul's Hospital, Vancouver, Canada, is a multidisciplinary University affiliated primary and specialty care clinic for HIV-infected patients. The clinic offers primary care and specialty consultation services, antiretroviral therapy distribution, and monitoring for HIV infected patients, and a specialty clinic for individuals with HCV co-infection. As per Canadian healthcare standards, all medical care, and medication costs for treatment of HIV, were offered free of charge. Patient cost of HCV treatment is deductiblebased according to income. Those on social assistance received all treatment free of charge.
Study population
Patients included in this study were HCV/HIV coinfected, aged 19 years or more, and were assessed for HCV therapy by a physician specializing in HCV treatment between January 1, 2002 and May 31, 2008 . Participants considered to be eligible for HCV treatment were referred for additional counseling for treatment with pegylated interferon and ribavirin. On the basis of contemporary guidelines [18] , individuals who had decompensated liver disease, or serious comorbidities, were not offered treatment.
The design and scope of this study was approved by the University of British Columbia Ethics Committee.
Treatment and follow-up
Baseline testing was done to rule out other causes of liver disease (e.g. Wilson's disease, hemachromatosis, a-1 antitrypsin, and autoimmune hepatitis). A liver biopsy was offered to all patients to examine for evidence of chronic inflammation and cirrhosis. Lack of liver biopsy did not preclude access to HCV treatment if other parameters of inflammation (e.g. liver enzymes) were present.
HCV treatment followed published British Columbia guidelines [18] . Briefly, individuals with HCV genotype 1 were treated for 48 weeks (there were no patients with subtypes 4, 5, and 6) and those with HCV genotype 2 or 3 were treated for 24 weeks. From 2007 onward, individuals with genotype 2 or 3 infection occasionally received longer courses based on treatment response [19] . Treatment included pegylated interferon and ribavirin (weight-based after 2005) as per the American Association for the Study of Liver Diseases guidelines [20] . Follow-up appointments with hematology panel, and liver enzyme assessment occurred every 2 weeks for the first 2 months, then at monthly intervals. CD4 counts were drawn for assessment at baseline, end of treatment, and at 6 months post-treatment. Genotype 1 patients had blood drawn for HCV viral load at 12 weeks to examine for early virologic response (EVR), whereas all had blood drawn at the end of treatment to evaluate the end of treatment response (ETR), and at 6 months post-therapy to evaluate SVR as a surrogate of HCV eradication. Any patient withdrawing from treatment was counted as having a detectable HCV viral load at each of the endpoints (EVR, ETR, and SVR) after which they discontinued the therapy.
Analyses
The primary outcome of this study was to determine the proportion of treatment-eligible patients referred for treatment counseling who underwent treatment for their HCV infection with pegylated interferon and ribavirin. Secondary outcomes focused on proportion completing treatment, EVR, ETR, and SVR. Analyses included descriptive summaries of patient demographic and clinical variables at baseline and post-treatment (if applicable). Bivariate analysis was done using Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables to compare patients who underwent treatment with those who did not. Sociodemographic and clinical characteristics which were significant (P < 0.05) in the bivariate analysis were entered into a multivariate logistic model to determine factors associated with starting treatment. The Wilcoxon signed rank sum test was used to compare baseline alanine aminotransferase (ALT) with post-treatment ALT (last available) for those who are undergoing treatment.
All analyses were conducted using SAS version 9.1.3 (SAS, Cary, North Carolina, USA). All significance tests are two-sided and P values of less than 0.05 were considered statistically significant.
Results
A total of 134 recalled HCV/HIV co-infected individuals presented for HCV therapy counseling and assessment. Sixty-four (48%) individuals initiated HCV treatment with ribavirin and pegylated interferon, whereas 70 (52%) did not. Of those opting for HCV treatment, demographic factors including age, sex, ethnicity, number of years of known infection with HCV, and highly active antiretroviral therapy (HAART) were not associated with opting in or out of HCV treatment. Laboratory factors not affecting HCV treatment uptake included platelet count, creatinine (though both patients with a creatinine higher than 150 went untreated), baseline CD4 count, and plasma HIV-1-RNA levels (Table 1) . Treatment uptake was not associated with having undergone liver biopsy, or the presence of mild versus moderate-to-severe liver disease as based on the Ishak-Knoddell score for liver biopsies available in 87 (65%) patients [21] . In bivariate analysis, significant factors promoting treatment uptake were being a man who has sex with men (MSM) (P = 0.008), and not using intravenous drugs (P < 0.001), (Table 1) , having a higher baseline ALT (P = 0.003) and a normal hemoglobin (P = 0.003), (Table 1) . There was a trend toward those with genotype 2 or 3 being treated more frequently than genotype 1 (P = 0.096) ( Table 1) . No patients with two or more baseline laboratory abnormalities (of creatinine, hemoglobin, platelets, and neutrophil count) underwent treatment (P = 0.018) ( Table 1 ). In multivariate analysis intravenous drug use (IDU) (odds ratio: 3.48; 95% confidence interval: 1.37-8.79; P = 0.009) and having low hemoglobin levels (odds ratio: 4.232; 95% confidence interval: 1.36-13.10; P = 0.013) were predictors of not entering treatment ( Table 2) . (Table 3 ).
Descriptive analyses of the baseline factors of treated individuals by SVR are shown in Table 3 . Median CD4 counts at treatment initiation, treatment end, and at 6 months post-therapy were 380 cells/mm 3 (Fig. 1b) . CD4 counts fell significantly from baseline to treatment end, and recovered significantly from treatment end to 6 months post-therapy (P < 0.001) in all cases. When baseline CD4 counts were compared with counts taken 6 months posttherapy, however, counts had recovered in those achieving SVR (P = 0.583), but remained significantly lower compared with baseline in those who failed in the therapy (P = 0.015).
Discussion
As a general rule, rates of HCV treatment uptake are very low. In our cohort, patients were already engaged in care, were prescreened as treatment-eligible based on known factors about their overall health, and were actively being called back to the clinic, thereby representing the subgroup of patients most likely to obtain treatment for HCV. Despite this, only 64 of 134 (48%) HCV/HIV-1 co-infected individuals in our cohort underwent HCV treatment. A recent study from Australia showed a treatment uptake of 76% for newly identified HCV positive patients, showing that under ideal circumstances, a majority of HCV infected patients can be treated [22] . These data are encouraging that the early offering of HCV therapy in combination with a supportive treatment environment can result in good SVR's for infected patients.
In our study, IDU and low hemoglobin were predictors in multivariate analysis of not entering HCV treatment. The majority of individuals in this study infected with HCV who were not IDU were MSM. When compared with IDU, MSMs may be more likely to be offered treatment because of physician perception of ability to adhere to treatment regimens. Alternatively, socioeconomic factors such as education may make MSMs more likely to accept treatment. With regard to the decreased HCV treatment uptake among those with low hemoglobin, we suspect that this acts as a surrogate for overall poorer health and nutrition [23] . This is supported by the fact that of nine patients with two or more baseline laboratory abnormalities, only one received treatment, whereas neither of the patients with creatinine more than 150 (above which there is an indication not to treat the patient) were treated, quite possibly because of concern over treatment toxicity.
Of those who underwent treatment, EVR was 68.8% (genotype 1 only), ETR was 76.6%, and SVR was 57.8% overall.
A recent Cochrane review of 14 studies in HCV/HIV co-infected patients reported SVR for genotype 1 or 4 to be 27%, whereas SVR for genotype 2 or 3 was 56% [24] . Interestingly, our results for genotype 2 or 3 infection in this population approximated the values expected, however, our outcomes in genotype 1 infection were much better and approximated results seen in studies of HCV monoinfection [25, 26] . The reasons for our more favorable outcomes for genotype 1 are not clear but may reflect the intensive degree of multidisciplinary care offered at the John Ruedy Immunodeficiency clinic, and improved adherence to treatment as a result.
Despite only 37 of 64 patients attaining eradication, almost all have experienced a decrease in ALT post-treatment regardless of whether virus was detectable at the end of the study. Considering that HIV/HCV co-infected individuals are more likely to progress to cirrhosis [8] [9] [10] , a decrease in ALT (a marker of inflammation in the liver), is likely to provide benefit to the patient. In addition, other studies have shown post-treatment decreases in fibrosis scores [27] , and HAART-related toxicity [28] , both of which are likely to represent the product of reduced inflammation. Our study is limited by measuring only one ALT in the 6 months post-treatment, further study regarding longterm affect on ALT is needed.
CD4 counts fell significantly in all treated patients, and recovered after treatment cessation as seen earlier [29] . In patients achieving SVR, CD4 counts recovered to baseline by 6 months post-treatment. Despite similar rates of HIV treatment, however, CD4 counts of patients who failed in the therapy remained significantly lower than baseline 6 months after HCV treatment. It has been reported earlier that HCV/HIV co-infected patients experience slower CD4 cell recovery after the initiation of HAART, and if not treated, increased CD4 cell decline when compared with HIV monoinfected patients [30] . This is reflected in our findings, and may be a product of increased immune activation from active HCV infection. More study is needed to fully elucidate the effect of HCV treatment outcomes on long-term CD4 cell counts.
Study conclusions were limited by the fact that no individuals with genotypes 4, 5, or 6 were treated in this study and as such no conclusions could be made in relation to these genotypes. Treatment uptake was calculated as a proportion of those who presented for HCV counseling and assessment, and thus only considers a small proportion of those infected with HCV. Study numbers, and in particular, the number of individuals undergoing the treatment, were small enough that only descriptive analysis could be carried out on the treatment group.
Further study would ideally include a greater number of patients so as to allow for multivariate analysis of the treatment group. Finally, study conclusions were limited by the fact that adherence to and doses of medications were not recorded sufficiently to comment on the effect of missed doses or dose adjustments on SVR. This is important, because individuals capable of taking at least 80% of ribavirin, and interferon doses for at least 80% of the prescribed treatment duration have significantly better rates of SVR over less adherent patients (the '80/ 80/80 rule') [31] . We are, thus, only able to speak of treated patients in general terms.
In conclusion, our study showed that even in the setting in which patients are prescreened for suitability for HCV treatment before being recalled to clinic, and treatment is affordable to the patient, treatment uptake is still only approximately 50%. Of those treated, genotype 2 or 3 outcomes approximated those of other studies in similar populations of HIV/HCV co-infected individuals, whereas genotype 1 outcomes were better. In addition, ALT (a marker of inflammation) post-treatment was diminished almost universally in those who underwent treatment for their HCV disease suggesting treatment benefit, independent of SVR. These results suggest that further efforts are needed to optimize the uptake of HCV treatment among HIV infected patients.
